

Glucagon-Like Peptides: Regulators of Cell Proliferation

Molecular Endocrinology

17, 161-171

DOI: [10.1210/me.2002-0306](https://doi.org/10.1210/me.2002-0306)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Efficacy of State Fair Employment Practices Commissions. <i>ILR Review</i> , 1969, 22, 559-567.	1.3	3
2	Gut peptides and type 2 diabetes mellitus treatment. <i>Current Diabetes Reports</i> , 2003, 3, 365-372.	1.7	117
3	Expression of TGF- α in neuroendocrine tumours of the distal colon and rectum. <i>Apmis</i> , 2003, 111, 931-939.	0.9	4
4	Parathyroid Hormone-Related Protein Induces Insulin Expression Through Activation of MAP Kinase-Specific Phosphatase-1 That Dephosphorylates c-Jun NH ₂ -Terminal Kinase in Pancreatic β -Cells. <i>Diabetes</i> , 2003, 52, 2720-2730.	0.3	39
5	cAMP promotes pancreatic β -cell survival via CREB-mediated induction of IRS2. <i>Genes and Development</i> , 2003, 17, 1575-1580.	2.7	491
6	Enhancing Incretin Action for the Treatment of Type 2 Diabetes. <i>Diabetes Care</i> , 2003, 26, 2929-2940.	4.3	510
7	Glucagon-Like Peptide 1 Inhibits Cell Apoptosis and Improves Glucose Responsiveness of Freshly Isolated Human Islets. <i>Endocrinology</i> , 2003, 144, 5149-5158.	1.4	593
8	International Union of Pharmacology. XXXV. The Glucagon Receptor Family. <i>Pharmacological Reviews</i> , 2003, 55, 167-194.	7.1	460
9	Cardiac Function in Mice Lacking the Glucagon-Like Peptide-1 Receptor. <i>Endocrinology</i> , 2003, 144, 2242-2252.	1.4	182
10	Glucagon-Like Peptide-1 and the Islet β -Cell: Augmentation of Cell Proliferation and Inhibition of Apoptosis. <i>Endocrinology</i> , 2003, 144, 5145-5148.	1.4	258
11	Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2004, 286, R269-R272.	0.9	87
12	Review: Pancreatic β -Cell Neogenesis Revisited. <i>Experimental Diabetes Research</i> , 2004, 5, 111-121.	1.0	45
13	GLP-1 Receptor Agonists and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes. <i>Hormone and Metabolic Research</i> , 2004, 36, 867-876.	0.7	202
14	Glucagon-like peptide 1 agonists and the development and growth of pancreatic β -cells. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2004, 286, E875-E881.	1.8	85
15	Minireview: Diversity and Complexity of Signaling through Peptidergic G Protein-Coupled Receptors. <i>Endocrinology</i> , 2004, 145, 2645-2652.	1.4	62
16	Cell-Surface Peptidases. <i>International Review of Cytology</i> , 2004, 235, 165-213.	6.2	92
17	Minireview: Glucagon-Like Peptides Regulate Cell Proliferation and Apoptosis in the Pancreas, Gut, and Central Nervous System. <i>Endocrinology</i> , 2004, 145, 2653-2659.	1.4	486
18	Signaling Elements Involved in the Metabolic Regulation of mTOR by Nutrients, Incretins, and Growth Factors in Islets. <i>Diabetes</i> , 2004, 53, S225-S232.	0.3	142

#	ARTICLE	IF	CITATIONS
19	Individual Subtypes of Enteroendocrine Cells in the Mouse Small Intestine Exhibit Unique Patterns of Inositol 1,4,5-trisphosphate Receptor Expression. <i>Journal of Histochemistry and Cytochemistry</i> , 2004, 52, 53-63.	1.3	17
20	Dexamethasone plus glucagon-like peptide 2 given to lactating rat dams has a late effect on intestinal lipid uptake in the weanling offspring. <i>Journal of Parenteral and Enteral Nutrition</i> , 2004, 28, 355-363.	1.3	6
21	RyR2 and Calpain-10 Delineate a Novel Apoptosis Pathway in Pancreatic Islets. <i>Journal of Biological Chemistry</i> , 2004, 279, 24794-24802.	1.6	124
22	Chronic Exposure to GLP-1R Agonists Promotes Homologous GLP-1 Receptor Desensitization In Vitro but Does Not Attenuate GLP-1R-Dependent Glucose Homeostasis In Vivo. <i>Diabetes</i> , 2004, 53, S205-S214.	0.3	67
23	Extrahypothalamic Expression of the Glucagon-Like Peptide-2 Receptor Is Coupled to Reduction of Glutamate-Induced Cell Death in Cultured Hippocampal Cells. <i>Endocrinology</i> , 2004, 145, 3495-3506.	1.4	69
24	Incretin mimetics: type 2 diabetes therapy beyond glucose control. <i>International Journal of Clinical Practice</i> , 2004, 58, 15-19.	0.8	0
25	A perspective on pancreatic stem/progenitor cells. <i>Pediatric Diabetes</i> , 2004, 5, 29-37.	1.2	18
26	Preventing microbial translocation in haematological malignancy. <i>British Journal of Haematology</i> , 2004, 125, 282-293.	1.2	22
27	A role for chemistry in stem cell biology. <i>Nature Biotechnology</i> , 2004, 22, 833-840.	9.4	297
28	Plasticity of the β^2 cell insulin secretory competence: preparing the pancreatic β^2 cell for the next meal. <i>Journal of Physiology</i> , 2004, 558, 369-380.	1.3	61
29	Prior in vitro exposure to GLP-1 with or without GIP can influence the subsequent beta cell responsiveness. <i>Biochemical Pharmacology</i> , 2004, 68, 33-39.	2.0	23
30	Bioactive GLP-1 in Gut, Receptor Expression in Pancreas, and Insulin Response to GLP-1 in Diabetes-Prone Rats. <i>Endocrine</i> , 2004, 23, 77-84.	2.2	5
31	Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications. <i>Diabetologia</i> , 2004, 47, 581-589.	2.9	366
32	Incretins, insulin secretion and Type 2 diabetes mellitus. <i>Diabetologia</i> , 2004, 47, 357-366.	2.9	371
33	Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. <i>Diabetologia</i> , 2004, 47, 806-815.	2.9	300
34	New Drugs for Management of Diabetes: Insulin Analogues, Inhaled Insulin, Pramlintide, and Novel Peptides. <i>Nutrition in Clinical Practice</i> , 2004, 19, 172-180.	1.1	5
35	Epac: A New cAMP-Binding Protein in Support of Glucagon-Like Peptide-1 Receptor-Mediated Signal Transduction in the Pancreatic β -Cell. <i>Diabetes</i> , 2004, 53, 5-13.	0.3	324
36	Gastro-intestinal hormones GIP and GLP-1. <i>Annales D'Endocrinologie</i> , 2004, 65, 13-21.	0.6	38

#	ARTICLE	IF	CITATIONS
37	Enhancement or prolongation of GLP-1 activity as a strategy for treatment of type 2 diabetes. Drug Discovery Today: Therapeutic Strategies, 2004, 1, 207-212.	0.5	8
38	The Engineering of Tissues Using Progenitor Cells. Current Topics in Developmental Biology, 2004, 64, 101-139.	1.0	20
40	Management of Type 2 Diabetes With Thiazolidinediones. , 2004, 14, 293-299.		7
41	Proglucagon-Derived Peptides: Mechanisms of Action and Therapeutic Potential. Physiology, 2005, 20, 357-365.	1.6	72
42	Beyond the scale: understanding mechanisms of weight gain and obesity in diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 2005, 12, 143-145.	0.6	0
43	Glucagon-like peptide-1: physiology and therapeutic potential. Current Opinion in Endocrinology, Diabetes and Obesity, 2005, 12, 56-62.	0.6	26
44	Gastrointestinal surgery and gut hormones. Current Opinion in Endocrinology, Diabetes and Obesity, 2005, 12, 89-98.	0.6	22
45	Glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase IV inhibitors: new therapeutic agents for the treatment of type 2 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 2005, 12, 146-151.	0.6	38
46	Class II G Protein-Coupled Receptors and Their Ligands in Neuronal Function and Protection. NeuroMolecular Medicine, 2005, 7, 003-036.	1.8	80
47	Is the 'Accelerator Hypothesis' worthy of our attention?. Diabetic Medicine, 2005, 22, 115-117.	1.2	14
48	Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nature Medicine, 2005, 11, 90-94.	15.2	1,298
49	Dietary lactitol fermentation increases circulating peptide YY and glucagon-like peptide-1 in rats and humans. Nutrition, 2005, 21, 1036-1043.	1.1	60
50	Development and resolution of experimental colitis in mice with targeted deletion of dipeptidyl peptidase IV. Journal of Cellular Physiology, 2005, 204, 687-692.	2.0	45
51	Glucagon-like peptide 1 (GLP-1) in biology and pathology. Diabetes/Metabolism Research and Reviews, 2005, 21, 91-117.	1.7	250
52	Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes. Diabetes/Metabolism Research and Reviews, 2005, 21, 313-331.	1.7	72
53	Suppression of Pdx-1 perturbs proinsulin processing, insulin secretion and GLP-1 signalling in INS-1 cells. Diabetologia, 2005, 48, 720-731.	2.9	68
54	Lipid malabsorption persists after weaning in rats whose dams were given GLP-2 and dexamethasone. Lipids, 2005, 40, 1141-1148.	0.7	3
55	Advances in the management of short bowel syndrome. Current Gastroenterology Reports, 2005, 7, 373-378.	1.1	15

#	ARTICLE	IF	CITATIONS
56	Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs. <i>Expert Opinion on Investigational Drugs</i> , 2005, 14, 57-64.	1.9	46
57	Bombesin and nutrients independently and additively regulate hormone release from GIP/Ins cells. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2005, 288, E208-E215.	1.8	14
58	Treatment of suckling rats with GLP-2 plus dexamethasone increases the ileal uptake of fatty acids in later life. <i>American Journal of Physiology - Renal Physiology</i> , 2005, 288, G54-G59.	1.6	5
59	Incretin Mimetics as Emerging Treatments for Type 2 Diabetes. <i>Annals of Pharmacotherapy</i> , 2005, 39, 110-118.	0.9	62
60	Pancreatic β -cells expressing GLP-1 are resistant to the toxic effects of immunosuppressive drugs. <i>Journal of Molecular Endocrinology</i> , 2005, 34, 377-390.	1.1	39
61	Involvement of endogenous glucagon-like peptide-1(7â€³36) amide on glycaemia-lowering effect of oligofructose in streptozotocin-treated rats. <i>Journal of Endocrinology</i> , 2005, 185, 457-465.	1.2	164
63	Biologic actions and therapeutic potential of the proglucagon-derived peptides. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2005, 1, 22-31.	2.9	200
64	Glucagon-like Peptide-1 Plasmid Construction and Delivery for the Treatment of Type 2 Diabetes. <i>Molecular Therapy</i> , 2005, 12, 885-891.	3.7	29
65	Glucagon-Like Peptide-1 as a Treatment Option for Type 2 Diabetes and Its Role in Restoring Beta-Cell Mass. <i>Diabetes Technology and Therapeutics</i> , 2005, 7, 651-657.	2.4	20
66	β -Cell Pdx1 Expression Is Essential for the Glucoregulatory, Proliferative, and Cytoprotective Actions of Glucagon-Like Peptide-1. <i>Diabetes</i> , 2005, 54, 482-491.	0.3	213
67	Systemic administration of pituitary adenylate cyclase-activating polypeptide maintains beta-cell mass and retards onset of hyperglycaemia in beta-cell-specific calmodulin-overexpressing transgenic mice. <i>European Journal of Endocrinology</i> , 2005, 152, 805-811.	1.9	8
68	Glucose-dependent Insulinotropic Polypeptide (GIP) Stimulation of Pancreatic β -Cell Survival Is Dependent upon Phosphatidylinositol 3-Kinase (PI3K)/Protein Kinase B (PKB) Signaling, Inactivation of the Forkhead Transcription Factor Foxo1, and Down-regulation of bax Expression. <i>Journal of Biological Chemistry</i> , 2005, 280, 22297-22307.	1.6	205
69	Basal Receptor Activation by Locally Produced Glucagon-Like Peptide-1 Contributes to Maintaining β -Cell Function. <i>Molecular Endocrinology</i> , 2005, 19, 1373-1382.	3.7	54
70	Inhibitors of Dipeptidyl Peptidase 4. <i>Annual Reports in Medicinal Chemistry</i> , 2005, , 149-165.	0.5	21
71	Regulation of pancreatic somatostatin gene expression by insulin and glucagon. <i>Molecular and Cellular Endocrinology</i> , 2005, 235, 31-37.	1.6	12
72	Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?. <i>Regulatory Peptides</i> , 2005, 128, 159-165.	1.9	158
73	A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness. <i>Regulatory Peptides</i> , 2005, 130, 1-6.	1.9	81
74	Glucagon-Like Peptide-1-Based Therapies for the Treatment of Type 2 Diabetes Mellitus. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2005, 4, 361-370.	1.8	63

#	ARTICLE	IF	CITATIONS
75	Over One Hundred Peptide-Activated G Protein-Coupled Receptors Recognize Ligands with Turn Structure. <i>Chemical Reviews</i> , 2005, 105, 793-826.	23.0	219
76	Therapeutic Approaches to Preserve Islet Mass in Type 2 Diabetes. <i>Annual Review of Medicine</i> , 2006, 57, 265-281.	5.0	135
77	Gastrointestinal Peptide Hormones Regulating Energy and Glucose Homeostasis. , 2006, , 161-181.		1
78	Exendin-4 Uses Irs2 Signaling to Mediate Pancreatic β Cell Growth and Function. <i>Journal of Biological Chemistry</i> , 2006, 281, 1159-1168.	1.6	189
79	Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus. <i>International Journal of Biochemistry and Cell Biology</i> , 2006, 38, 845-859.	1.2	85
80	Growth factors and beta cell replication. <i>International Journal of Biochemistry and Cell Biology</i> , 2006, 38, 931-950.	1.2	120
81	Islet neogenesis: A potential therapeutic tool in type 1 diabetes. <i>International Journal of Biochemistry and Cell Biology</i> , 2006, 38, 498-503.	1.2	12
82	Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus. <i>International Journal of Biochemistry and Cell Biology</i> , 2006, 38, 860-872.	1.2	44
83	Islet neogenesis: A potential therapeutic tool in type 1 diabetes. <i>International Journal of Biochemistry and Cell Biology</i> , 2006, 38, 715-720.	1.2	12
84	Glucagon-like peptide 2 inhibits ghrelin secretion in humans. <i>Regulatory Peptides</i> , 2006, 137, 173-178.	1.9	15
85	Regulation of Gastrointestinal Normal Cell Growth. , 2006, , 435-458.		0
87	Exenatide: From the Gila Monster to the Pharmacy. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2006, 46, 44-55.	0.7	41
89	Vesicular storage and secretion of l-glutamate from glucagon-like peptide 1-secreting clonal intestinal L cells. <i>Journal of Neurochemistry</i> , 2006, 96, 550-560.	2.1	23
90	DPP-4 inhibitors and their potential role in the management of type 2 diabetes. <i>International Journal of Clinical Practice</i> , 2006, 60, 1454-1470.	0.8	311
91	Synergy of glucose and growth hormone signalling in islet cells through ICA512 and STAT5. <i>Nature Cell Biology</i> , 2006, 8, 435-445.	4.6	74
92	Digestive Adaptation with Intestinal Reserve: A Neuroendocrine-Based Operation for Morbid Obesity. <i>Obesity Surgery</i> , 2006, 16, 1371-1379.	1.1	75
93	Morphology of the pancreas of some species belonging to the genera <i>Phelsuma</i> and <i>Gecko</i> (family) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 211, 413-421.	1.5	9
94	Chromosome 2 locus Nidd5 has a potent effect on adiposity in the TSOD mouse. <i>Mammalian Genome</i> , 2006, 17, 375-384.	1.0	29

#	ARTICLE	IF	CITATIONS
95	Incretin Mimetics and Dipeptidyl Peptidase-IV Inhibitors: Potential New Therapies for Type 2 Diabetes Mellitus. <i>Pharmacotherapy</i> , 2006, 26, 360-374.	1.2	33
96	Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. <i>British Journal of Surgery</i> , 2006, 93, 210-215.	0.1	289
97	Mechanisms of transcriptional regulation underlying temporal integration of signals. <i>Nucleic Acids Research</i> , 2006, 34, 5175-5183.	6.5	18
98	Role of the Exchange Protein Directly Activated by Cyclic Adenosine 5'-Monophosphate (Epac) Pathway in Regulating Proglucagon Gene Expression in Intestinal Endocrine L Cells. <i>Endocrinology</i> , 2006, 147, 3727-3736.	1.4	45
99	New Insights Into Glucose Regulation. <i>The Diabetes Educator</i> , 2006, 32, 221-228.	2.6	20
100	Glucagon and Glucagon-Like Peptide Receptors as Drug Targets. <i>Current Pharmaceutical Design</i> , 2006, 12, 1731-1750.	0.9	82
101	Activation of Glucagon-Like Peptide-1 Receptor Signaling Does Not Modify the Growth or Apoptosis of Human Pancreatic Cancer Cells. <i>Diabetes</i> , 2006, 55, 1369-1379.	0.3	52
102	Exenatide. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 411-418.	0.5	38
103	Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus. <i>Expert Review of Endocrinology and Metabolism</i> , 2006, 1, 329-341.	1.2	21
104	A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. <i>Current Medical Research and Opinion</i> , 2007, 23, 1493-1507.	0.9	55
105	Glucagon-like peptide 2 has limited efficacy to increase nutrient absorption in fetal and preterm pigs. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2007, 293, R2179-R2184.	0.9	17
106	Incretin Receptors for Glucagon-Like Peptide 1 and Glucose-Dependent Insulinotropic Polypeptide Are Essential for the Sustained Metabolic Actions of Vildagliptin in Mice. <i>Diabetes</i> , 2007, 56, 3006-3013.	0.3	145
107	Bone resorption is decreased postprandially by intestinal factors and glucagon-like peptide-2 is a possible candidate. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 814-820.	0.6	37
108	The regulation of the lymphatic secretion of glucagon-like peptide-1 (GLP-1) by intestinal absorption of fat and carbohydrate. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 293, G963-G971.	1.6	46
109	GLP-1 as a Therapeutic Agent in Patients with Type 2 Diabetes Mellitus. <i>Recent Patents on Endocrine, Metabolic & Immune Drug Discovery</i> , 2007, 1, 193-201.	0.7	0
110	Dipeptidyl Peptidase-IV Inhibitors: An Evolving Treatment for Type 2 Diabetes from the Incretin Concept. <i>Recent Patents on Endocrine, Metabolic & Immune Drug Discovery</i> , 2007, 1, 15-24.	0.7	26
111	β-Cell Failure in Diabetes and Preservation by Clinical Treatment. <i>Endocrine Reviews</i> , 2007, 28, 187-218.	8.9	624
112	Glucagon-Like Peptide 1 and Type 1 Diabetes: NOD Ready for Prime Time?. <i>Endocrinology</i> , 2007, 148, 5133-5135.	1.4	8

#	ARTICLE	IF	CITATIONS
113	Ileitis alters neuronal and enteroendocrine signalling in guinea pig distal colon. <i>Gut</i> , 2007, 56, 186-194.	6.1	51
114	Multiple Peptide Synthesis to Identify Bioactive Hormone Structures. , 2007, , 243-288.		4
115	Glucagon-Like Peptide-1 and Energy Homeostasis ³ . <i>Journal of Nutrition</i> , 2007, 137, 2534S-2538S.	1.3	47
116	Proliferation, Hyperplasia, Neogenesis, and Neoplasia in the Islets of Langerhans. <i>Pancreas</i> , 2007, 35, 199-206.	0.5	19
117	Effect of Exenatide on β Cell Function After Islet Transplantation in Type 1 Diabetes. <i>Transplantation</i> , 2007, 83, 24-28.	0.5	121
118	Putting the pieces of the puzzle together – a series of hypotheses on the etiology and pathogenesis of type 1 diabetes. <i>Medical Hypotheses</i> , 2007, 68, 607-619.	0.8	23
119	Protection of pancreatic β -cells by exendin-4 may involve the reduction of endoplasmic reticulum stress; in vivo and in vitro studies. <i>Journal of Endocrinology</i> , 2007, 193, 65-74.	1.2	90
120	Exenatide. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2593-2608.	0.9	70
121	Biology of Incretins: GLP-1 and GIP. <i>Gastroenterology</i> , 2007, 132, 2131-2157.	0.6	2,918
122	Glucagon-Like Peptide-1 and Its Receptor Agonist Exendin-4 Modulate Cholangiocyte Adaptive Response to Cholestasis. <i>Gastroenterology</i> , 2007, 133, 244-255.	0.6	73
123	New Insights into the Understanding of Gastrointestinal Dysmotility. <i>Drug Target Insights</i> , 2007, 2, 117739280700200.	0.9	1
124	Reversal of hyperglycemia in diabetic rats by portal vein transplantation of islet-like cells generated from bone marrow mesenchymal stem cells. <i>World Journal of Gastroenterology</i> , 2007, 13, 3342.	1.4	107
125	PDX-1/VP16 Overexpression Induce the Transdifferentiation of Canine Adult Pancreatic Cells into Beta-cells. <i>The Journal of Korean Diabetes Association</i> , 2007, 31, 51.	0.1	3
126	Type 2 Diabetes and Cardiovascular Disease: Reducing the Risk. <i>Journal of Managed Care Pharmacy</i> , 2007, 13, 1-17.	2.2	13
127	Transcriptional response of pancreatic beta cells to metabolic stimulation: large scale identification of immediate-early and secondary response genes. <i>BMC Molecular Biology</i> , 2007, 8, 54.	3.0	45
128	Dietary pectin stimulates protein metabolism in the digestive tract. <i>Nutrition</i> , 2007, 23, 69-75.	1.1	46
129	Proliferation of sorted human and rat beta cells. <i>Diabetologia</i> , 2007, 51, 91-100.	2.9	213
130	Management of type 2 diabetes: the GLP-1 pathway. <i>Future Prescriber</i> , 2008, 9, 18-24.	0.1	3

#	ARTICLE	IF	CITATIONS
131	Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*. <i>Diabetes, Obesity and Metabolism</i> , 2008, 10, 675-682.	2.2	113
132	Changes in gut hormones after bariatric surgery. <i>Clinical Endocrinology</i> , 2008, 69, 173-179.	1.2	83
133	Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. <i>Journal of Controlled Release</i> , 2008, 132, 171-183.	4.8	1,835
134	An Albumin-Exendin-4 Conjugate Engages Central and Peripheral Circuits Regulating Murine Energy and Glucose Homeostasis. <i>Gastroenterology</i> , 2008, 134, 1137-1147.	0.6	119
135	Glucagon Receptor Signaling Is Essential for Control of Murine Hepatocyte Survival. <i>Gastroenterology</i> , 2008, 135, 2096-2106.	0.6	51
136	Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4810-4817.	1.8	180
137	Role of the incretin system in the remission of type 2 diabetes following bariatric surgery. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008, 18, 574-579.	1.1	44
138	The incretins: From the concept to their use in the treatment of type 2 diabetes. Part A: Incretins: Concept and physiological functions. <i>Diabetes and Metabolism</i> , 2008, 34, 550-559.	1.4	65
139	Glucagon-like peptide-1 in type 2 diabetes: the β -cell and beyond. <i>Diabetes, Obesity and Metabolism</i> , 2008, 10, 2-13.	2.2	18
140	Suppressive effects of glucagon-like peptide-1 on interferon- γ -induced nitric oxide production in insulin-producing cells is mediated by inhibition of tumor necrosis factor- α production. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 334-340.	1.8	4
141	In the Italian population sexual dimorphism affects pre-natal thyroid migration but not biochemical severity of gland ectopia and pre-natal bone maturation. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 341-345.	1.8	3
142	Unmet needs among patients with Type 2 diabetes and secondary failure to oral anti-diabetic agents. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 371-379.	1.8	15
143	Insulin Action in the Double Incretin Receptor Knockout Mouse. <i>Diabetes</i> , 2008, 57, 288-297.	0.3	31
144	Glucose-Dependent Insulinotropic Polypeptide-Mediated Up-Regulation of β -Cell Antiapoptotic <i>Bcl-2</i> Gene Expression Is Coordinated by Cyclic AMP (cAMP) Response Element Binding Protein (CREB) and cAMP-Responsive CREB Coactivator 2. <i>Molecular and Cellular Biology</i> , 2008, 28, 1644-1656.	1.1	123
145	The entero-insular axis: implications for human metabolism. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008, 46, 43-56.	1.4	42
146	Preserving insulin secretion in Type 2 diabetes mellitus. <i>Expert Review of Endocrinology and Metabolism</i> , 2008, 3, 147-159.	1.2	5
147	Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. <i>Journal of Clinical Pathology</i> , 2008, 61, 401-409.	1.0	53
148	Beyond Glycemic Control. <i>The Diabetes Educator</i> , 2008, 34, 66S-72S.	2.6	3

#	ARTICLE	IF	CITATIONS
149	Pancreatic Islet Immunoreactivity to the Reg Protein INGAP. <i>Journal of Histochemistry and Cytochemistry</i> , 2008, 56, 183-191.	1.3	16
150	Cytokines and β -Cell Biology: from Concept to Clinical Translation. <i>Endocrine Reviews</i> , 2008, 29, 334-350.	8.9	201
151	Exenatide: incretin therapy for patients with Type 2 diabetes mellitus. <i>Expert Review of Endocrinology and Metabolism</i> , 2008, 3, 671-690.	1.2	5
152	Endocrinology of the Gastrointestinal Tract and Modulation of Satiety. , 2008, , 211-246.		0
153	The Reg Family Member INGAP Is a Marker of Endocrine Patterning in the Embryonic Pancreas. <i>Pancreas</i> , 2008, 36, 1-9.	0.5	21
154	Exendin-4 Treatment Expands Graft β -Cell Mass in Diabetic Mice Transplanted with a Marginal Number of Fresh Islets. <i>Cell Transplantation</i> , 2008, 17, 641-647.	1.2	19
155	Combination Therapy with Glucagon-Like Peptide-1 and Gastrin Induces β -Cell Neogenesis from Pancreatic Duct Cells in Human Islets Transplanted in Immunodeficient Diabetic Mice. <i>Cell Transplantation</i> , 2008, 17, 631-640.	1.2	67
156	Long-Term Insulin Independence and Improvement in Insulin Secretion After Supplemental Islet Infusion Under Exenatide and Etanercept. <i>Transplantation</i> , 2008, 86, 1658-1665.	0.5	92
157	Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. <i>Frontiers in Bioscience - Landmark</i> , 2008, Volume, 3648.	3.0	69
158	DPP-4 Inhibitors and the Relations between Rosiglitazone and the Risk of Myocardial Infarction. <i>Journal of the Korean Medical Association</i> , 2008, 51, 371.	0.1	2
159	Long-Term Metabolic and Hormonal Effects of Exenatide on Islet Transplant Recipients with Allograft Dysfunction. <i>Cell Transplantation</i> , 2009, 18, 1247-1259.	1.2	48
160	Administration of anti-glucagon-like peptide-2 serum suppresses epithelial cell proliferation of the distal small intestine in weanling rats. <i>Biomedical Research</i> , 2009, 30, 259-261.	0.3	3
161	The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone. <i>Diabetes Care</i> , 2009, 32, 1649-1655.	4.3	391
162	Reversal of Diabetes in Rats Using GLP-1-Expressing Adult Pancreatic Duct-Like Precursor Cells Transformed From Acinar to Ductal Cells. <i>Stem Cells and Development</i> , 2009, 18, 991-1002.	1.1	9
163	DPP-4 Inhibitors in Clinical Practice. <i>Postgraduate Medicine</i> , 2009, 121, 70-100.	0.9	34
164	The Role of Parathyroid Hormone-Related Protein (PTHrP) in the Pathophysiology of Diabetes Mellitus. <i>Mini-Reviews in Medicinal Chemistry</i> , 2009, 9, 717-723.	1.1	6
165	New Potential Adjuncts to Treatment of Children With Type 1 Diabetes Mellitus. <i>Pediatric Research</i> , 2009, 65, 370-374.	1.1	13
166	Recent Advances in Antidiabetic Drug Therapies Targeting the Enteroinsular Axis. <i>Current Drug Metabolism</i> , 2009, 10, 125-137.	0.7	45

#	ARTICLE	IF	CITATIONS
167	Elevated basal and post-feed glucagon-like peptide 1 (GLP-1) concentrations in the neonatal period. <i>European Journal of Endocrinology</i> , 2009, 160, 53-58.	1.9	29
168	Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis. <i>Gut</i> , 2009, 58, 990-997.	6.1	58
169	Deletion of Fas in the pancreatic β -cells leads to enhanced insulin secretion. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009, 297, E1304-E1312.	1.8	19
170	Cholangiocyte proliferation and liver fibrosis. <i>Expert Reviews in Molecular Medicine</i> , 2009, 11, e7.	1.6	167
171	Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor) Tj ETQq0 0 0 rgBT /Overlock 10 Tf		169
172	From pumps to prevention: recent advances in the treatment of type 1 diabetes. <i>Drug Discovery Today</i> , 2009, 14, 973-981.	3.2	10
173	Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. <i>Advances in Therapy</i> , 2009, 26, 249-262.	1.3	81
174	Perinatal survivin is essential for the establishment of pancreatic beta cell mass in mice. <i>Diabetologia</i> , 2009, 52, 2130-2141.	2.9	26
175	Obesity, Gut Hormones, and Bariatric Surgery. <i>World Journal of Surgery</i> , 2009, 33, 1983-1988.	0.8	56
176	Incretin-based therapies: Therapeutic rationale and pharmacological promise for type 2 diabetes. <i>Journal of the American Academy of Nurse Practitioners</i> , 2009, 21, 623-630.	1.4	11
177	Growth factor control of pancreatic islet regeneration and function. <i>Pediatric Diabetes</i> , 2009, 10, 14-32.	1.2	63
178	Targeting the Incretin System in Type 2 Diabetes Mellitus. <i>Mount Sinai Journal of Medicine</i> , 2009, 76, 244-256.	1.9	5
179	Ciliary neurotrophic factor recruitment of glucagon-like peptide-1 mediates neurogenesis, allowing immortalization of adult murine hypothalamic neurons. <i>FASEB Journal</i> , 2009, 23, 4256-4265.	0.2	92
180	Differential expression of glucagon and glucagon-like peptide 1 receptors in mouse pancreatic alpha and beta cells in two models of alpha cell hyperplasia. <i>Molecular and Cellular Endocrinology</i> , 2009, 311, 69-76.	1.6	36
181	Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. <i>Kidney International</i> , 2009, 75, 1272-1277.	2.6	280
182	Diagnosis and Management of Hyperinsulinemic Hypoglycemia. , 2009, , 493-506.		2
183	Eleven Amino Acid Glucagon-like Peptide-1 Receptor Agonists with Antidiabetic Activity. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 7788-7799.	2.9	61
184	Role of cyclic AMP signaling in the production and function of the incretin hormone glucagon-like peptide-1. <i>Science Foundation in China</i> , 2009, 16, 23-35.	0.3	0

#	ARTICLE	IF	CITATIONS
185	Type 2 Diabetes Mellitus: New Genetic Insights will Lead to New Therapeutics. <i>Current Genomics</i> , 2009, 10, 110-118.	0.7	34
186	Preventing Type 2 Diabetes Mellitus: Room for Residual Risk Reduction After Lifestyle Changes?. <i>Current Pharmaceutical Design</i> , 2010, 16, 3839-3847.	0.9	11
187	Pdx-1 Regulation of the INGAP Promoter Involves Sequestration of NeuroD Into a Non-DNA-Binding Complex. <i>Pancreas</i> , 2010, 39, 64-70.	0.5	5
188	Saxagliptin. <i>Cardiology in Review</i> , 2010, 18, 213-217.	0.6	10
189	Gut Hypertrophy After Gastric Bypass Is Associated With Increased Glucagon-Like Peptide 2 and Intestinal Crypt Cell Proliferation. <i>Annals of Surgery</i> , 2010, 252, 50-56.	2.1	153
190	Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2010, 298, E634-E643.	1.8	102
191	Cyclic AMP Signaling in Pancreatic Islets. <i>Advances in Experimental Medicine and Biology</i> , 2010, 654, 281-304.	0.8	89
192	Update 1 of: Over One Hundred Peptide-Activated G Protein-Coupled Receptors Recognize Ligands with Turn Structure. <i>Chemical Reviews</i> , 2010, 110, PR1-PR41.	23.0	66
193	Glycaemic control in type 2 diabetes: Targets and new therapies. , 2010, 125, 328-361.		155
195	Gene Expression Profiles of Colonic Mucosa in Healthy Young Adult and Senior Dogs. <i>PLoS ONE</i> , 2010, 5, e12882.	1.1	10
196	Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment. <i>Vascular Health and Risk Management</i> , 2010, 6, 671.	1.0	17
197	Treatment of diabetes with glucagon-like peptide-1 gene therapy. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 1681-1692.	1.4	11
199	Maternal deprivation alters epithelial secretory cell lineages in rat duodenum: role of CRF-related peptides. <i>Gut</i> , 2010, 59, 744-751.	6.1	42
200	Saxagliptina, un nuevo inhibidor de la DPP-4 en el tratamiento de la diabetes mellitus tipo 2: aspectos novedosos. <i>Avances En Diabetología</i> , 2010, 26, 445-447.	0.1	0
201	Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors. <i>Mayo Clinic Proceedings</i> , 2010, 85, S27-S37.	1.4	41
202	Recent advances in the regulation of cholangiocyte proliferation and function during extrahepatic cholestasis. <i>Digestive and Liver Disease</i> , 2010, 42, 245-252.	0.4	30
203	Cecal and Colonic Responses in Rats Fed 5 or 30% Corn Oil Diets Containing Either 7.5% Broccoli Dietary Fiber or Microcrystalline Cellulose. <i>Journal of Agricultural and Food Chemistry</i> , 2010, 58, 6510-6515.	2.4	38
204	Mechanisms facilitating weight loss and resolution of type 2 diabetes following bariatric surgery. <i>Trends in Endocrinology and Metabolism</i> , 2010, 21, 337-344.	3.1	100

#	ARTICLE	IF	CITATIONS
205	The incretin system and cardiometabolic disease. Canadian Journal of Cardiology, 2010, 26, 87-95.	0.8	14
206	Epac2-Dependent Rap1 Activation and the Control of Islet Insulin Secretion by Glucagon-Like Peptide-1. Vitamins and Hormones, 2010, 84, 279-302.	0.7	61
207	Involvement of ERK1/2 signalling and growth-related moleculesâ€™ expression in response to heat stress-induced damage in rat jejunum and IEC-6 cells. International Journal of Hyperthermia, 2010, 26, 538-555.	1.1	29
208	Neuroprotective properties of GLP-1: theoretical and practical applications. Current Medical Research and Opinion, 2011, 27, 547-558.	0.9	125
209	Preservation of Î²-Cell Function: The Key to Diabetes Prevention. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2354-2366.	1.8	207
210	Regulation of Biliary Proliferation by Neuroendocrine Factors. American Journal of Pathology, 2011, 178, 472-484.	1.9	31
211	GLP-1 analogs containing disulfide bond exhibited prolonged half-life in vivo than GLP-1. Peptides, 2011, 32, 1303-1312.	1.2	32
212	Organic consequences of ileal transposition in rats with diet-induced obesity. Nature Precedings, 2011, , .	0.1	0
213	Gut Hormones Restrict Neurodegeneration in Parkinsonâ€™s Disease. , 2011, , .		3
214	Place in Therapy for Liraglutide and Saxagliptin for Type 2 Diabetes. Southern Medical Journal, 2011, 104, 426-439.	0.3	2
215	Histological study of the role of stem cells on experimentally induced diabetes mellitus. Egyptian Journal of Histology, 2011, 34, 849-858.	0.0	0
216	Advances in the Treatment of Type 2 Diabetes Mellitus. American Journal of Therapeutics, 2011, 18, 117-152.	0.5	134
217	Transcriptional regulation of <i>Î±</i> cell differentiation. Diabetes, Obesity and Metabolism, 2011, 13, 13-20.	2.2	49
218	Diabetes resolution and hyperinsulinaemia after metabolic Rouxâ€™enâ€™Y gastric bypass. Obesity Reviews, 2011, 12, e257-72.	3.1	80
219	Long-term, antidiabetogenic effects of GLP-1 gene therapy using a double-stranded, adeno-associated viral vector. Gene Therapy, 2011, 18, 155-163.	2.3	12
220	Making progress: preserving beta cells in type 1 diabetes. Annals of the New York Academy of Sciences, 2011, 1243, 119-134.	1.8	24
221	Addition of metformin to exogenous glucagon-like peptideâ€™1 results in increased serum glucagon-like peptideâ€™1 concentrations and greater glucose lowering in type 2 diabetes mellitus. Metabolism: Clinical and Experimental, 2011, 60, 52-56.	1.5	36
222	Whey protein. Nutrafoods, 2011, 10, 17-22.	0.5	0

#	ARTICLE	IF	CITATIONS
223	Advances in the Etiology and Management of Hyperinsulinemic Hypoglycemia After Roux-en-Y Gastric Bypass. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 1879-1888.	0.9	60
224	Connexin Implication in the Control of the Murine Beta-Cell Mass. <i>Pediatric Research</i> , 2011, 70, 142-147.	1.1	22
225	Activation of the GLP-1 Receptor Signalling Pathway: A Relevant Strategy to Repair a Deficient Beta-Cell Mass. <i>Experimental Diabetes Research</i> , 2011, 2011, 1-11.	3.8	50
226	Incretin-Related Therapies in Type 2 Diabetes: A Practical Overview. <i>Diabetes Spectrum</i> , 2011, 24, 26-35.	0.4	7
227	Glucagon-Like Peptide-1 Receptor Activation Inhibits Growth and Augments Apoptosis in Murine CT26 Colon Cancer Cells. <i>Endocrinology</i> , 2011, 152, 3362-3372.	1.4	92
228	The emerging role of the intestine in metabolic diseases. <i>Archives of Physiology and Biochemistry</i> , 2011, 117, 165-176.	1.0	18
229	Incretin-Based Therapy and the Quest for Sustained Improvements in β -Cell Health. <i>Diabetes Care</i> , 2011, 34, 2133-2135.	4.3	22
230	New gene targets for glucagon-like peptide-1 during embryonic development and in undifferentiated pluripotent cells. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2011, 301, E494-E503.	1.8	3
231	Structural and Molecular Conservation of Glucagon-Like Peptide-1 and Its Receptor Confers Selective Ligand-Receptor Interaction. <i>Frontiers in Endocrinology</i> , 2012, 3, 141.	1.5	31
232	Oreocnide integrifolia Flavonoids Augment Reprogramming for Islet Neogenesis and β -Cell Regeneration in Pancreatectomized BALB/c Mice. <i>Evidence-based Complementary and Alternative Medicine</i> , 2012, 2012, 1-13.	0.5	7
233	Exendin-4 ameliorates diabetic symptoms through activation of glucokinase. <i>Journal of Diabetes</i> , 2012, 4, 369-377.	0.8	14
234	Diabetes-Associated Common Genetic Variation and Its Association With GLP-1 Concentrations and Response to Exogenous GLP-1. <i>Diabetes</i> , 2012, 61, 1082-1089.	0.3	36
235	Glucagonlike Peptide 2 Protects Intestinal Barrier in Severe Acute Pancreatitis Through Regulating Intestinal Epithelial Cell Proliferation and Apoptosis. <i>Pancreas</i> , 2012, 41, 1080-1085.	0.5	15
236	Stability and Bioactivity Studies on Dipeptidyl Peptidase IV Resistant Glucogan-like Peptide-1 Analogues. <i>Protein and Peptide Letters</i> , 2012, 19, 203-211.	0.4	5
237	Early Diagnosis of Pancreatic Adenocarcinoma. <i>Pancreas</i> , 2012, 41, 663-670.	0.5	9
238	Inhibition of Dipeptidyl Peptidase-4 (DPP-4): A Target to Treat Type 2 Diabetes. <i>Current Enzyme Inhibition</i> , 2012, 7, 205-217.	0.3	5
239	Imaging of β -Cell Mass and Insulinitis in Insulin-Dependent (Type 1) Diabetes Mellitus. <i>Endocrine Reviews</i> , 2012, 33, 892-919.	8.9	48
240	Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice. <i>Regulatory Peptides</i> , 2012, 179, 91-100.	1.9	81

#	ARTICLE	IF	CITATIONS
241	Cellular Changes of the Corneal Epithelium and Stroma in Herpes Simplex Keratitis. <i>Ophthalmology</i> , 2012, 119, 1791-1797.	2.5	61
242	Incretin-based Therapies (Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4) Tj ETQq1 1 0.784314 rgBT /Overlock 11	0.4	3
243	Formation of cyclic structure at amino-terminus of glucagon-like peptide-1 exhibited a prolonged half-life in vivo. <i>Diabetes Research and Clinical Practice</i> , 2012, 96, 362-370.	1.1	1
244	Exendin-4 directly improves endothelial dysfunction in isolated aortas from obese rats through the cAMP or AMPK/eNOS pathways. <i>Diabetes Research and Clinical Practice</i> , 2012, 97, 453-460.	1.1	45
245	Induction of beta-cell resistance to hypoxia and technologies for oxygen delivery to transplanted pancreatic islets. <i>Diabetes/Metabolism Research and Reviews</i> , 2012, 28, 475-484.	1.7	21
246	Regulation of Mouse Intestinal L Cell Progenitors Proliferation by the Glucagon Family of Peptides. <i>Endocrinology</i> , 2012, 153, 3076-3088.	1.4	23
247	Novel GLP-1 receptor agonists for diabetes. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 45-57.	1.9	61
248	Î±-cell role in Î²-cell generation and regeneration. <i>Islets</i> , 2012, 4, 188-198.	0.9	59
249	Cost Effectiveness of Saxagliptin and Metformin versus Sulfonylurea and Metformin in the Treatment of Type 2 Diabetes Mellitus in Germany. <i>Clinical Drug Investigation</i> , 2012, 32, 189-202.	1.1	38
250	The biliary tree is a reservoir of multipotent stem cells. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2012, 9, 231-240.	8.2	187
251	Exendin-4 improved rat cortical neuron survival under oxygen/glucose deprivation through PKA pathway. <i>Neuroscience</i> , 2012, 226, 388-396.	1.1	39
252	Deletion of GÎ±Z Protein Protects against Diet-induced Glucose Intolerance via Expansion of Î²-Cell Mass. <i>Journal of Biological Chemistry</i> , 2012, 287, 20344-20355.	1.6	39
253	Partial Small Bowel Resection with Sleeve Gastrectomy Increases Adiponectin Levels and Improves Glucose Homeostasis in Obese Rodents with Type 2 Diabetes. <i>World Journal of Surgery</i> , 2012, 36, 1432-1438.	0.8	5
254	Self-assembling glucagon-like peptide 1-mimetic peptide amphiphiles for enhanced activity and proliferation of insulin-secreting cells. <i>Acta Biomaterialia</i> , 2012, 8, 1685-1692.	4.1	35
255	Effect of glucagon-like peptide-1 gene expression on graft function in mouse islet transplantation. <i>Transplant International</i> , 2012, 25, 242-249.	0.8	8
256	Self-inducible secretion of glucagon-like peptide-1 (GLP-1) that allows MIN6 cells to maintain insulin secretion and insure cell survival. <i>Molecular and Cellular Endocrinology</i> , 2012, 349, 281-288.	1.6	9
257	Impact of albumin on drug delivery - New applications on the horizon. <i>Journal of Controlled Release</i> , 2012, 157, 4-28.	4.8	702
258	Efficient GLP-1 gene delivery using two-step transcription amplification plasmid system with a secretion signal peptide and arginine-grafted bioreducible polymer. <i>Journal of Controlled Release</i> , 2012, 157, 243-248.	4.8	14

#	ARTICLE	IF	CITATIONS
259	Clinical impact of serum proteins on drug delivery. <i>Journal of Controlled Release</i> , 2012, 161, 429-445.	4.8	319
260	Type 2 Diabetes Mellitus: A Possible Surgically Reversible Intestinal Dysfunction. <i>Obesity Surgery</i> , 2012, 22, 167-176.	1.1	25
261	Nanospaces between endoplasmic reticulum and mitochondria as control centres of pancreatic β -cell metabolism and survival. <i>Protoplasma</i> , 2012, 249, 49-58.	1.0	11
262	Glucagon-like peptide-1 (GLP-1) and protective effects in cardiovascular disease: a new therapeutic approach for myocardial protection. <i>Cardiovascular Diabetology</i> , 2013, 12, 90.	2.7	37
265	Long-term effects of gastric bypass and duodenal switch on systemic exposure of atorvastatin. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2013, 27, 2094-2101.	1.3	34
266	GLP-1 could improve the similarity of IPCs and pancreatic beta cells in cellular ultrastructure and function. <i>Journal of Cellular Biochemistry</i> , 2013, 114, 2221-2230.	1.2	0
267	A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection. <i>Journal of Controlled Release</i> , 2013, 172, 144-151.	4.8	92
268	Peptidomic Profiling of Secreted Products from Pancreatic Islet Culture Results in a Higher Yield of Full-length Peptide Hormones than Found using Cell Lysis Procedures. <i>Journal of Proteome Research</i> , 2013, 12, 3610-3619.	1.8	38
269	Systematic analysis of a dipeptide library for inhibitor development using human dipeptidyl peptidase IV produced by a <i>Saccharomyces cerevisiae</i> expression system. <i>Biochemical and Biophysical Research Communications</i> , 2013, 430, 1217-1222.	1.0	23
270	Acute peripheral GLP-1 receptor agonism or antagonism does not alter energy expenditure in rats after Roux-en-Y gastric bypass. <i>Physiology and Behavior</i> , 2013, 121, 70-78.	1.0	31
271	Incretin-based therapies in the treatment of type 2 diabetes " More than meets the eye?. <i>European Journal of Internal Medicine</i> , 2013, 24, 207-212.	1.0	39
272	The ductal origin of structural and functional heterogeneity between pancreatic islets. <i>Progress in Histochemistry and Cytochemistry</i> , 2013, 48, 103-140.	5.1	21
274	Design and Synthesis of 4-(2,4,5-Trifluorophenyl)butane-1,3-diamines as Dipeptidyl Peptidase...IV Inhibitors. <i>ChemMedChem</i> , 2013, 8, 1104-1116.	1.6	10
275	Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action. <i>Cell Metabolism</i> , 2013, 17, 819-837.	7.2	1,088
276	Beyond Glycemic Control in Diabetes Mellitus: Effects of Incretin-Based Therapies on Bone Metabolism. <i>Frontiers in Endocrinology</i> , 2013, 4, 73.	1.5	36
277	β -Cells are dispensable in postnatal morphogenesis and maturation of mouse pancreatic islets. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013, 305, E1030-E1040.	1.8	32
278	Biological effects of bariatric surgery on obesity-related comorbidities. <i>Canadian Journal of Surgery</i> , 2013, 56, 47-57.	0.5	107
279	Early Insulinization to Prevent Diabetes Progression. <i>Diabetes Care</i> , 2013, 36, S190-S197.	4.3	24

#	ARTICLE	IF	CITATIONS
280	Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPER. <i>Frontiers in Endocrinology</i> , 2013, 4, 50.	1.5	15
281	Incretin-Based Therapy for Type 2 Diabetes Mellitus. <i>American Journal of Therapeutics</i> , 2013, 20, 384-393.	0.5	7
282	The G Protein-coupled Receptor Family C Group 6 Subtype A (GPC6A) Receptor Is Involved in Amino Acid-induced Glucagon-like Peptide-1 Secretion from GLUTag Cells. <i>Journal of Biological Chemistry</i> , 2013, 288, 4513-4521.	1.6	125
283	Improved transplantation outcome through delivery of DNA encoding secretion signal peptide-linked glucagon-like peptide-1 into mouse islets. <i>Transplant International</i> , 2013, 26, 443-452.	0.8	4
284	Glucagon-like peptide-1: modulator of β -cell dysfunction and death. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 185-192.	2.2	22
285	Improved function and proliferation of adult human beta cells engrafted in diabetic immunodeficient NOD-scid IL2r γ ;null mice treated with alogliptin. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2013, 6, 493.	1.1	15
286	Dipeptidyl Peptidase IV Inhibition Activates CREB and Improves Islet Vascularization through VEGF-A/VEGFR-2 Signaling Pathway. <i>PLoS ONE</i> , 2013, 8, e82639.	1.1	24
287	A Novel Glucagon-Related Peptide (GCRP) and Its Receptor GCRPR Account for Coevolution of Their Family Members in Vertebrates. <i>PLoS ONE</i> , 2013, 8, e65420.	1.1	28
288	Dipeptidyl Peptidase-IV Inhibitory Activity of Peptides in Porcine Skin Gelatin Hydrolysates. , 0, , .		15
289	A Novel Long-Acting Glucagon-Like Peptide-1 Agonist with Improved Efficacy in Insulin Secretion and β -Cell Growth. <i>Endocrinology and Metabolism</i> , 2014, 29, 320.	1.3	11
290	Antihyperglycaemic therapies and cancer risk. <i>Diabetes and Vascular Disease Research</i> , 2014, 11, 371-389.	0.9	30
291	The latest pharmacotherapy options for type 1 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 37-49.	0.9	14
292	Hyperinsulinaemic Hypoglycaemia. <i>Hormone and Metabolic Research</i> , 2014, 46, 157-170.	0.7	40
293	Effects of Dipeptidyl Peptidase-4 Inhibition with MK-0431 on Syngeneic Mouse Islet Transplantation. <i>International Journal of Endocrinology</i> , 2014, 2014, 1-5.	0.6	2
295	Regulation of Glucose Homeostasis by GLP-1. <i>Progress in Molecular Biology and Translational Science</i> , 2014, 121, 23-65.	0.9	184
296	GLP-2 Suppresses LPS-Induced Inflammation in Macrophages by Inhibiting ERK Phosphorylation and NF- κ B Activation. <i>Cellular Physiology and Biochemistry</i> , 2014, 34, 590-602.	1.1	40
297	Calorie Restriction is a Major Determinant of the Short-Term Metabolic Effects of Gastric Bypass Surgery in Obese Type 2 Diabetic Patients. <i>Clinical Endocrinology</i> , 2014, 80, 834-842.	1.2	71
298	Insulin dysregulation. <i>Equine Veterinary Journal</i> , 2014, 46, 103-112.	0.9	156

#	ARTICLE	IF	CITATIONS
299	The Effect of Bariatric Surgery on Intestinal Absorption and Transit Time. <i>Obesity Surgery</i> , 2014, 24, 796-805.	1.1	96
300	Long-Acting GLP-1 Analogue in V-Shaped Conformation by Terminal Polylysine Modifications. <i>Molecular Pharmaceutics</i> , 2014, 11, 4092-4099.	2.3	17
301	Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2014, 307, E630-E643.	1.8	53
302	Therapies for inter-relating diabetes and obesity – GLP-1 and obesity. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2487-2500.	0.9	37
303	Activation of GPR40 attenuates chronic inflammation induced impact on pancreatic β -cells health and function. <i>BMC Cell Biology</i> , 2014, 15, 24.	3.0	29
304	Gut microbiota, probiotics and diabetes. <i>Nutrition Journal</i> , 2014, 13, 60.	1.5	266
305	MOLECULAR EVOLUTION OF GPCRS: GLP1/GLP1 receptors. <i>Journal of Molecular Endocrinology</i> , 2014, 52, T15-T27.	1.1	18
306	A molecular connection of <i>Pterocarpus marsupium</i> , <i>Eugenia jambolana</i> and <i>Gymnema sylvestre</i> with dipeptidyl peptidase-4 in the treatment of diabetes. <i>Pharmaceutical Biology</i> , 2014, 52, 268-271.	1.3	24
307	Distribution of Glucagon-Like Peptide (GLP)-2-Immunoreactive Cells in the Chicken Small Intestine: Antigen Retrieval Immunohistochemistry. <i>Journal of Veterinary Medical Science</i> , 2014, 76, 565-568.	0.3	14
308	Expression of Glucagon-Like Peptide 1 Receptor during Osteogenic Differentiation of Adipose-Derived Stem Cells. <i>Endocrinology and Metabolism</i> , 2014, 29, 567.	1.3	27
309	Immunological Identification of Vesicular Nucleotide Transporter in Intestinal L Cells. <i>Biological and Pharmaceutical Bulletin</i> , 2014, 37, 1090-1095.	0.6	9
310	GLP-1 ameliorates the proliferation activity of INS-1 cells inhibited by intermittent high glucose concentrations through the regulation of cyclins. <i>Molecular Medicine Reports</i> , 2014, 10, 683-688.	1.1	9
311	Effects of Bariatric Surgery on Comorbid Conditions Associated with Morbid Obesity. , 2015, , 71-84.		0
312	Lixisenatide accelerates restoration of normoglycemia and improves human beta-cell function and survival in diabetic immunodeficient NOD–scid IL-2r γ null RIP-DTR mice engrafted with human islets. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2015, 8, 387.	1.1	13
313	Steering Endogenous Butyrate Production in the Intestinal Tract of Broilers as a Tool to Improve Gut Health. <i>Frontiers in Veterinary Science</i> , 2015, 2, 75.	0.9	112
314	The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A – Me Too – or – the Special One – Antidiabetic Class?. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-28.	1.0	65
315	Plasma peptidases as prognostic biomarkers in patients with first-episode psychosis. <i>Psychiatry Research</i> , 2015, 228, 197-202.	1.7	6
316	Post-Gastric Bypass Hyperinsulinemic Hypoglycemia: Fructose is a Carbohydrate Which Can Be Safely Consumed. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3097-3102.	1.8	18

#	ARTICLE	IF	CITATIONS
317	Metabolic Mechanisms in Obesity and Type 2 Diabetes: Insights from Bariatric/Metabolic Surgery. <i>Obesity Facts</i> , 2015, 8, 350-363.	1.6	53
318	Liraglutide prevents fast weight gain and β^2 -cell dysfunction in male catch-up growth rats. <i>Experimental Biology and Medicine</i> , 2015, 240, 1165-1176.	1.1	8
319	The protective effect of GLP-1 analogue in arterial calcification through attenuating osteoblastic differentiation of human VSMCs. <i>International Journal of Cardiology</i> , 2015, 189, 188-193.	0.8	34
320	Multistage pH-responsive mucoadhesive nanocarriers prepared by aerosol flow reactor technology: A controlled dual protein-drug delivery system. <i>Biomaterials</i> , 2015, 68, 9-20.	5.7	77
321	Differential effects of Roux-en-Y gastric bypass surgery on brown and beige adipose tissue thermogenesis. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 1240-1249.	1.5	18
322	Ligand Binding Pocket Formed by Evolutionarily Conserved Residues in the Glucagon-like Peptide-1 (GLP-1) Receptor Core Domain. <i>Journal of Biological Chemistry</i> , 2015, 290, 5696-5706.	1.6	24
323	A live-cell, high-content imaging survey of 206 endogenous factors across five stress conditions reveals context-dependent survival effects in mouse primary beta cells. <i>Diabetologia</i> , 2015, 58, 1239-1249.	2.9	10
324	The structure of wheat bread influences the postprandial metabolic response in healthy men. <i>Food and Function</i> , 2015, 6, 3236-3248.	2.1	30
325	Glucagon-like peptide 2 counteracts the mucosal damage and the neuropathy induced by chronic treatment with cisplatin in the mouse gastric fundus. <i>Neurogastroenterology and Motility</i> , 2016, 28, 206-216.	1.6	34
326	Variant fatty acid-like molecules Conjugation, novel approaches for extending the stability of therapeutic peptides. <i>Scientific Reports</i> , 2016, 5, 18039.	1.6	27
328	Co-culture of clonal beta cells with GLP-1 and glucagon-secreting cell line impacts on beta cell insulin secretion, proliferation and susceptibility to cytotoxins. <i>Biochimie</i> , 2016, 125, 119-125.	1.3	9
329	Exendin-4 protects bone marrow-derived mesenchymal stem cells against oxygen/glucose and serum deprivation-induced apoptosis through the activation of the cAMP/PKA signaling pathway and the attenuation of ER stress. <i>International Journal of Molecular Medicine</i> , 2016, 37, 889-900.	1.8	37
330	The regulation of function, growth and survival of GLP-1-producing L-cells. <i>Clinical Science</i> , 2016, 130, 79-91.	1.8	31
331	Complete metabolome and lipidome analysis reveals novel biomarkers in the human diabetic corneal stroma. <i>Experimental Eye Research</i> , 2016, 153, 90-100.	1.2	46
332	Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2016, 12, 566-592.	4.3	292
333	The prolonged effect of glucagon-like peptide 2 pretreatment on growth performance and intestinal development of weaned piglets. <i>Journal of Animal Science and Biotechnology</i> , 2016, 7, 28.	2.1	10
334	G protein-coupled receptors as targets for anti-diabetic therapeutics. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 161-172.	21.5	90
335	Duodenojejunal Bypass Leads to Altered Gut Microbiota and Strengthened Epithelial Barriers in Rats. <i>Obesity Surgery</i> , 2016, 26, 1576-1583.	1.1	23

#	ARTICLE	IF	CITATIONS
336	The pivotal role of high glucose-induced overexpression of PKC δ in the appearance of glucagon-like peptide-1 resistance in endothelial cells. <i>Endocrine</i> , 2016, 54, 396-410.	1.1	10
337	Insulin Secretion. , 2016, , 546-555.e5.		3
338	Difference in postprandial GLP-1 response despite similar glucose kinetics after consumption of wheat breads with different particle size in healthy men. <i>European Journal of Nutrition</i> , 2017, 56, 1063-1076.	1.8	25
339	Myricetin: a potent approach for the treatment of type 2 diabetes as a natural class B GPCR agonist. <i>FASEB Journal</i> , 2017, 31, 2603-2611.	0.2	59
340	Regulators of Cholangiocyte Proliferation. <i>Gene Expression</i> , 2017, 17, 155-171.	0.5	47
341	Exendin-4 protects HUVECs from tunicamycin-induced apoptosis via inhibiting the IRE1 α /JNK/caspase-3 pathway. <i>Endocrine</i> , 2017, 55, 764-772.	1.1	15
342	Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), extracellular signal-related kinase (ERK)1/2, and cAMP/protein kinase A (PKA) signaling pathways involving β -catenin. <i>Experimental Cell Research</i> , 2017, 360, 281-291.	1.2	54
343	Irinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 233-249.	1.1	14
344	Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 59-75.	1.4	29
345	Role of Incretin Axis in Inflammatory Bowel Disease. <i>Frontiers in Immunology</i> , 2017, 8, 1734.	2.2	43
346	The Role of Glucagon-Like Peptide 1 (GLP1) in Type 3 Diabetes: GLP-1 Controls Insulin Resistance, Neuroinflammation and Neurogenesis in the Brain. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2493.	1.8	52
347	Involvement of CRF2 signaling in enterocyte differentiation. <i>World Journal of Gastroenterology</i> , 2017, 23, 5127.	1.4	14
348	Polylactic Acid Nanopillar Array-Driven Osteogenic Differentiation of Human Adipose-Derived Stem Cells Determined by Pillar Diameter. <i>Nano Letters</i> , 2018, 18, 2243-2253.	4.5	92
349	Analysis of potential genes and pathways associated with the colorectal normal mucosa to adenoma to carcinoma sequence. <i>Cancer Medicine</i> , 2018, 7, 2555-2566.	1.3	42
350	Efficacy of vildagliptin for prevention of postpartum diabetes in women with a recent history of insulin-requiring gestational diabetes: A phase II, randomized, double-blind, placebo-controlled study. <i>Molecular Metabolism</i> , 2018, 9, 168-175.	3.0	12
351	Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 207-217.	1.5	10
352	The role of chitosan on oral delivery of peptide-loaded nanoparticle formulation. <i>Journal of Drug Targeting</i> , 2018, 26, 551-562.	2.1	47
353	A DSSS Signal Detection Method Based on Wavelet Decomposition and Delay Multiplication. , 2018, , .		4

#	ARTICLE	IF	CITATIONS
354	Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1. <i>Frontiers in Endocrinology</i> , 2018, 9, 584.	1.5	54
355	Porcine Neonatal Pancreatic Cell Clusters Maintain Their Multipotency in Culture and After Transplantation. <i>Scientific Reports</i> , 2018, 8, 8212.	1.6	10
356	Interactions of Gut Endocrine Cells with Epithelium and Neurons. , 2018, 8, 1019-1030.		13
357	No Guts, No Loss: Toward the Ideal Treatment for Obesity in the Twenty-First Century. <i>Frontiers in Endocrinology</i> , 2018, 9, 442.	1.5	22
358	Nanoparticles induced by embedding self-assembling cassette into glucagon-like peptide 1 for improving in vivo stability. <i>FASEB Journal</i> , 2018, 32, 2992-3004.	0.2	10
359	Incretin Hormones: The Link between Glycemic Index and Cardiometabolic Diseases. <i>Nutrients</i> , 2019, 11, 1878.	1.7	14
360	Liraglutide inhibits the apoptosis of human nucleus pulposus cells induced by high glucose through PI3K/Akt/caspase-3 signaling pathway. <i>Bioscience Reports</i> , 2019, 39, .	1.1	15
361	Liraglutide protects high-glucose-stimulated fibroblasts by activating the CD36-JNK-AP1 pathway to downregulate P4HA1. <i>Biomedicine and Pharmacotherapy</i> , 2019, 118, 109224.	2.5	17
362	Enteroinsular axis response to carbohydrates and fasting in healthy newborn foals. <i>Journal of Veterinary Internal Medicine</i> , 2019, 33, 2752-2764.	0.6	9
363	The beneficial effects of a muscarinic agonist on pancreatic β^2 -cells. <i>Scientific Reports</i> , 2019, 9, 16180.	1.6	11
364	The Role of Oxidative Stress and Hormones in Controlling Obesity. <i>Frontiers in Endocrinology</i> , 2019, 10, 540.	1.5	57
365	Micro- and Nano-hemispherical 3D Imprints Modulate the Osteogenic Differentiation and Mineralization Tendency of Bone Cells. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 35513-35524.	4.0	16
366	Vector-free in vivo trans-determination of adult hepatic stem cells to insulin-producing cells. <i>Molecular Biology Reports</i> , 2019, 46, 5501-5509.	1.0	2
367	Outcomes of metabolic surgery in obese patients with type 2 diabetes with respect to impact on beta cell function, insulin sensitivity and diabetes remission - A study from south India. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 1829-1835.	1.8	4
368	Inhibition of ssc-microRNA-140-5p ameliorates the Clostridium perfringens beta2 toxin-induced inflammatory response in IPEC-J2 cells via the ERK1/2 and JNK pathways by targeting VEGFA. <i>Molecular Immunology</i> , 2020, 127, 12-20.	1.0	6
369	Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: A double-blind, randomized, placebo-controlled study. <i>Journal of Diabetes and Its Complications</i> . 2020. 34. 107548.	1.2	17
370	Implanted islet mass influences the effects of dipeptidyl peptidase-IV inhibitor LAF237 on transplantation outcomes in diabetic mice. <i>Biomedical Journal</i> , 2020, , .	1.4	1
371	Super-assembled core/shell fibrous frameworks with dual growth factors for <i>in situ</i> cementum-ligament-bone complex regeneration. <i>Biomaterials Science</i> , 2020, 8, 2459-2471.	2.6	21

#	ARTICLE	IF	CITATIONS
372	Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1307, 171-192.	0.8	64
373	Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders. <i>Current Research in Pharmacology and Drug Discovery</i> , 2021, 2, 100022.	1.7	5
374	Novel advances in understanding fatty acid-binding G protein-coupled receptors and their roles in controlling energy balance. <i>Nutrition Reviews</i> , 2022, 80, 187-199.	2.6	6
375	Islet β cells physiological difference study of old and young mice based on single-cell transcriptomics. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1775-1783.	1.1	3
376	An effective surface modification strategy to boost PEEK osteogenesis using porous CaP generated in well-tuned collagen matrix. <i>Applied Surface Science</i> , 2021, 555, 149571.	3.1	3
377	circGLI3 Inhibits Oxidative Stress by Regulating the miR-339-5p/VEGFA Axis in IPEC-J2 Cells. <i>BioMed Research International</i> , 2021, 2021, 1-19.	0.9	1
378	DBPR108, a novel dipeptidyl peptidase-4 inhibitor with antihyperglycemic activity. <i>Life Sciences</i> , 2021, 278, 119574.	2.0	7
379	The Gut and Type 2 Diabetes Mellitus. , 2020, , 375-393.		1
381	Repurposing GLP1 agonists for neurodegenerative diseases. <i>International Review of Neurobiology</i> , 2020, 155, 91-112.	0.9	7
382	Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. <i>Journal of Clinical Investigation</i> , 2004, 113, 1571-1581.	3.9	188
383	Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. <i>Journal of Clinical Investigation</i> , 2007, 117, 143-152.	3.9	241
384	The role of gut hormones in glucose homeostasis. <i>Journal of Clinical Investigation</i> , 2007, 117, 24-32.	3.9	510
385	Loss of enteroendocrine cells in mice alters lipid absorption and glucose homeostasis and impairs postnatal survival. <i>Journal of Clinical Investigation</i> , 2010, 120, 1708-1721.	3.9	83
386	Nonclassical Islet Peptides: Pancreatic and Extrapancreatic Actions. <i>Clinical Medicine Insights: Endocrinology and Diabetes</i> , 2019, 12, 117955141988887.	1.0	12
387	Genome-Wide Screening of Genes Regulated by DNA Methylation in Colon Cancer Development. <i>PLoS ONE</i> , 2012, 7, e46215.	1.1	37
388	Chronic Treatment with the GLP1 Analogue Liraglutide Increases Cell Proliferation and Differentiation into Neurons in an AD Mouse Model. <i>PLoS ONE</i> , 2013, 8, e58784.	1.1	103
389	Prolactin Receptors and Placental Lactogen Drive Male Mouse Pancreatic Islets to Pregnancy-Related mRNA Changes. <i>PLoS ONE</i> , 2015, 10, e0121868.	1.1	39
390	Liraglutide Inhibits the Apoptosis of MC3T3-E1 Cells Induced by Serum Deprivation through cAMP/PKA/ β -Catenin and PI3K/AKT/GSK3 β Signaling Pathways. <i>Molecules and Cells</i> , 2018, 41, 234-243.	1.0	20

#	ARTICLE	IF	CITATIONS
391	Incretin levels in patients with hypothyroidism and the evaluation of incretin levels alterations with treatment. <i>Asian Biomedicine</i> , 2019, 13, 3-9.	0.2	1
392	Teneligliptin enhances the beneficial effects of GLP-1 in endothelial cells exposed to hyperglycemic conditions. <i>Oncotarget</i> , 2018, 9, 8898-8910.	0.8	11
393	New Therapeutic Strategies for the Treatment of Type 2 Diabetes Mellitus Based on Incretins. <i>Review of Diabetic Studies</i> , 2005, 2, 61-61.	0.5	31
394	Incretin Therapy – Present and Future. <i>Review of Diabetic Studies</i> , 2011, 8, 307-322.	0.5	24
395	Developments of Glucagon Like Peptide-1 (GLP-1) and Long-acting Analogs in Clinical and Preclinical Studies for Treatment of Type 2 Diabetes. <i>Current Pharmaceutical Biotechnology</i> , 2014, 14, 835-841.	0.9	3
396	Role of the Glucagon-like Peptide-1 Receptor Agonist in Maintaining Pluripotency in Human Embryonic Stem Cells. <i>Open Stem Cell Journal</i> , 2011, 3, 11-22.	2.0	4
397	Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in mice. <i>Frontiers in Bioscience - Landmark</i> , 2008, Volume, 6850.	3.0	43
398	Neuroprotective Effects and Treatment Potential of Incretin Mimetics in a Murine Model of Mild Traumatic Brain Injury. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 356.	1.8	29
399	Optimizing diabetes treatment in the presence of obesity. <i>Cleveland Clinic Journal of Medicine</i> , 2017, 84, S22-S29.	0.6	12
400	Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus. <i>Indian Journal of Endocrinology and Metabolism</i> , 2011, 15, 9.	0.2	25
401	Pleiotropic effects of incretins. <i>Indian Journal of Endocrinology and Metabolism</i> , 2012, 16, 47.	0.2	28
402	Both sitagliptin analogue & pioglitazone preserve the β^2 -cell proportion in the islets with different mechanism in non-obese and obese diabetic mice. <i>BMB Reports</i> , 2011, 44, 713-718.	1.1	16
403	Bioactive Food Peptides in Health and Disease. , 2013, , .		15
404	Enteroglucagon. , 2004, , 709-715.		0
405	Metabolic Actions of Glucagon-Like Peptides. <i>Oxidative Stress and Disease</i> , 2005, , .	0.3	0
406	Gastrointestinale Hormonsysteme und ihre Regulation. , 2006, , 261-290.		0
407	Glucagonlike Peptides 1 and 2, Enteroglucagon, Glicentin, and Oxyntomodulin. , 2006, , 1057-1064.		0
408	Treatment Strategies for Type 2 Diabetes Based on Incretin Action. , 2007, , 159-169.		2

#	ARTICLE	IF	CITATIONS
409	Type 2 Diabetes Mellitus: An Evidence-Based Approach to Practical Management. , 2008, , 151-167.		1
410	The Relationship Between the Insulin Receptor Substrates and Metabolic Disease. , 2008, , 255-278.		0
411	Glucagon-like Peptides and Insulin Sensitivity. , 2008, , 233-254.		0
413	Glucagon and the Glucagon-Like Peptides. , 2010, , 660-672.		0
414	Recent Advances in the Pathogenesis of Pancreatic Endocrine Neoplasms. , 2010, , 237-268.		0
415	Glucagon-like Peptide-1 and-2 Levels in Children with Diabetic Ketoacidosis. JCRPE Journal of Clinical Research in Pediatric Endocrinology, 2011, 1, 144-150.	0.4	0
416	Gastrointestinal Tract and Endocrine System. , 2013, , 983-1022.		0
417	Sleeve Gastrectomy in Metabolic Syndrome for Nonmorbid Obese Patients: Is this the Future for Diabetes Treatment?. World Journal of Laparoscopic Surgery, 2015, 8, 75-80.	0.2	0
418	Insulinoma. , 2015, , 179-197.		0
419	Gastrointestinal Tract and Endocrine System. , 2016, , 179-221.		0
420	In Tune with the World Trends: Clinical Aspects of Liraglutide Use in Combination with Insulin in Patients with Diabetes Mellitus (Literature Review and Clinical Observations). MÅ-Å¼narodnij EndokrinologÅ-Å½nj Å½urnal, 2016, .	0.1	1
421	Inkretini u patogenezi dijabetesa tipa 2. Medicinski Glasnik Specijalne Bolnice Za Bolesti Åtitaste Å½lezde I Bolesti Metabolizma Zlatibor, 2018, 23, 40-52.	0.1	0
422	Role of incretins in the pathogenesis of type 2 diabetes. Medicinski Glasnik Specijalne Bolnice Za Bolesti Åtitaste Å½lezde I Bolesti Metabolizma Zlatibor, 2018, 23, 53-65.	0.1	0
423	Pediatric Diabetes: Review Article. Indian Journal of Public Health Research and Development, 2019, 10, 2641.	0.1	0
424	Estrogen Promotes cAMP Production in Mesenchymal Stem Cells by Regulating ADCY2. International Journal of Stem Cells, 2020, 13, 55-64.	0.8	9
425	Phytochemicals modulate pancreatic islet Î² cell function through glucagon-like peptide-1-related mechanisms. Biochemical Pharmacology, 2022, 197, 114817.	2.0	4
426	Introducing, OncoTarget. Oncotarget, 2010, 1, 2-2.	0.8	0
427	Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Medscape Journal of Medicine, 2008, 10, 171.	0.6	35

#	ARTICLE	IF	CITATIONS
428	New insights into the understanding of gastrointestinal dysmotility. Drug Target Insights, 2007, 2, 229-37.	0.9	0
429	Dietary carbohydrate modifies the density of L cells in the chicken ileum. Journal of Veterinary Medical Science, 2022, 84, 265-274.	0.3	1
430	Comparison of expression profiles between undifferentiated and differentiated porcine IPEC-J2 cells. Porcine Health Management, 2022, 8, 4.	0.9	3
431	Preventing Oxidative Stress in the Liver: An Opportunity for GLP-1 and/or PASK. Antioxidants, 2021, 10, 2028.	2.2	6
436	MODERN MEANS AND APPROACHES TO TREATMENT FOR DIABETES MELLITUS TYPE 2. Problemy ZdorovĚ1Äč I Äkologii, 2012, , 23-27.	0.0	0
437	Probiotic Effects on Disease Prevention and Treatment. , 0, , .		0
442	Lessons Learned from Clinical Trials of Islet Transplantation. , 2023, , 499-527.		0